Abstract

This study was designed to compare the performance of GeneXpert® and GenomEra® group B streptococcus (GBS) PCR assays, held up against standard culture of GBS performed with and without broth pre-enrichment. In Denmark, the strategy for preventing early onset GBS infection (EOGBS) is risk factor based. Three hundred and sixty six women fulfilling one or more of the criteria for presence of risk factors for EOGBS were prospectively included. Rectovaginal swab samples were taken intrapartum and tested bed-site by the GenomEra® and the GeneXpert® GBS PCR assays and cultured at the microbiology laboratory using Granada agar plates with and without prior growth of sampling material in selective enrichment broth. Among 366 participants tested intrapartum, 99 were GBS-positive by culture, 95 by GenomEra, and 95 by GeneXpert. Compared with culture, the GenomEra and the GeneXpert performed with a sensitivity of 91.8% and 91.7% and a specificity of 98.1% and 97.3%, respectively. A combined reference standard was established by defining true positives as either culture-positive samples or culture-negative samples where both the GeneXpert and the GenomEra GBS PCR assays were positive. Using this, the sensitivity increased to 92.2% and the specificity to 99.6% for GenomEra and to 92.0% and 96.8% for GeneXpert. The use of selective broth enrichment found only three additional GBS culture-positive samples. The performance of the two PCR methods examined was very similar and close to the findings by culture, and both PCR assays are thus applicable as rapid intrapartum bed-site tests.

Highlights

  • Preventing neonatal infection with group B streptococci (GBS) still receives substantial attention from researchers worldwide aiming at the ideal identification and prevention of intrapartum transmission of GBS from mother to baby

  • IAP is given to women with one or more of the following five risk factors: (1) previous infant with GBS infection, (2) bacteriuria during the

  • Seven false-positive PCR test results were not available for further analyses since they were discarded with the test cassettes used in the PCR assays run at the maternity ward

Read more

Summary

Introduction

Preventing neonatal infection with group B streptococci (GBS) still receives substantial attention from researchers worldwide aiming at the ideal identification and prevention of intrapartum transmission of GBS from mother to baby. Early-onset GBS disease (EOGBS) is still the most frequent. Colonization rates with GBS in pregnant women vary from 10 to 35% by culture of screening samples from gestational weeks 35–37 [3,4,5]. There are two well-known strategies for preventing EOGBS in the newborn. One is universal culture-based antenatal screening for GBS colonization in all pregnant women in gestational weeks 35–37 and treatment of all GBS positive women during labor. The other strategy is based on risk assessment alone and is used in Denmark. IAP is given to women with one or more of the following five risk factors: (1) previous infant with GBS infection, (2) bacteriuria during the

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call